Current Perspectives of Anticoagulation in Patients With COVID-19
- PMID: 32569013
- DOI: 10.1097/FJC.0000000000000861
Current Perspectives of Anticoagulation in Patients With COVID-19
Abstract
Thromboembolism and myocardial injury is common in patients with COVID-19. Low-molecular-weight heparin appears to be associated with a good prognosis in patients with COVID-19 and has the ability to reduce coagulation and inflammation markers. Hospitalized patients with COVID-19 should be placed on thromboprophylaxis with the option of full therapeutic anticoagulation or tissue plasminogen activator in high-risk or mechanically ventilated patients. Thromboprophylaxis should also be considered at hospital discharge for high-risk patients. Clinical judgment should be used to evaluate the bleeding and safety risk of anticoagulation in patients with COVID-19 without confirmed data.
Similar articles
-
Venous Thromboembolism and Heparin Use in COVID-19 Patients: Juggling between Pragmatic Choices, Suggestions of Medical Societies and the Lack of Guidelines.J Thromb Thrombolysis. 2020 Jul;50(1):68-71. doi: 10.1007/s11239-020-02125-4. J Thromb Thrombolysis. 2020. PMID: 32367471 Free PMC article. No abstract available.
-
ISTH DIC subcommittee communication on anticoagulation in COVID-19.J Thromb Haemost. 2020 Sep;18(9):2138-2144. doi: 10.1111/jth.15004. J Thromb Haemost. 2020. PMID: 32881336 Free PMC article.
-
Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial.Trials. 2020 Sep 9;21(1):770. doi: 10.1186/s13063-020-04678-4. Trials. 2020. PMID: 32907635 Free PMC article.
-
COVID-19 update: Covid-19-associated coagulopathy.J Thromb Thrombolysis. 2020 Jul;50(1):54-67. doi: 10.1007/s11239-020-02134-3. J Thromb Thrombolysis. 2020. PMID: 32415579 Free PMC article. Review. No abstract available.
-
Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis.J Thromb Thrombolysis. 2020 Nov;50(4):814-821. doi: 10.1007/s11239-020-02235-z. J Thromb Thrombolysis. 2020. PMID: 32748122 Free PMC article.
Cited by
-
Neurological implications of COVID-19: a review of the science and clinical guidance.BMJ Neurol Open. 2020 Dec 14;2(2):e000101. doi: 10.1136/bmjno-2020-000101. eCollection 2020. BMJ Neurol Open. 2020. PMID: 33681805 Free PMC article. Review.
-
Safety and Efficacy of Apixaban For Therapeutic Anticoagulation in Critically Ill ICU Patients with Severe COVID-19 Respiratory Disease.TH Open. 2020 Nov 23;4(4):e376-e382. doi: 10.1055/s-0040-1720962. eCollection 2020 Oct. TH Open. 2020. PMID: 33244512 Free PMC article.
-
Retrospective Analyses Associate Hemostasis Activation Biomarkers With Poor Outcomes in Patients With COVID-19.Am J Clin Pathol. 2021 Mar 15;155(4):498-505. doi: 10.1093/ajcp/aqaa266. Am J Clin Pathol. 2021. PMID: 33300981 Free PMC article.
-
Thrombosis in Coronavirus disease 2019 (COVID-19) through the prism of Virchow's triad.Clin Rheumatol. 2020 Sep;39(9):2529-2543. doi: 10.1007/s10067-020-05275-1. Epub 2020 Jul 11. Clin Rheumatol. 2020. PMID: 32654082 Free PMC article. Review.
-
Ethnic differences in thromboprophylaxis for COVID-19 patients: should they be considered?Int J Hematol. 2021 Mar;113(3):330-336. doi: 10.1007/s12185-021-03078-x. Epub 2021 Jan 20. Int J Hematol. 2021. PMID: 33471294 Free PMC article. Review.
References
-
- Kang Y, Chen T, Mui D, et al. Cardiovascular manifestations and treatment considerations in covid-19. Heart. 2020. doi: 10.1136/heartjnl-2020-317056. - DOI
-
- Mao L, Jin H, Wang M, et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020:e201127. doi: 10.1001/jamaneurol.2020.1127. - DOI
-
- Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. doi: 10.1001/jamacardio.2020.0950.
-
- Emanueli C, Badimon L, Marteli F, et al. On behalf of the EU-CardioRNA COST Action (CA17129), Call to action for the cardiovascular side of COVID-19: a call for cooperative action from the EU-CardioRNA COST Action. Eur Heart J. doi: 10.1093/eurheartj/ehaa301.
-
- Zhang T, Sun LX, Feng RE, et al. Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E040.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical